CTC can be used for early screening of tumors. By testing the blood, doctors can know whether the patient has cancer and how high the risk is. On the other hand, monitoring the condition of patients with known cancer means telling him whether the treatment is effective or not, and also telling the doctor whether the patient has cancer or not. You should not switch to another treatment plan.
 
In terms of disease monitoring, taking immunotherapy as an example, the current standard method to determine whether a patient is suitable for immunotherapy is to take a biopsy of the patient's tumor tissue sample. Through tumor marker technology, patients do not need to undergo surgery. They only need to draw blood and simply analyze the relevant protein information on the surface of cancer cells to know whether the patient is suitable for immunotherapy drugs or therapies. The results are more accurate than tissue testing. Accurate.

Precision nano-CTC cancer screening technology has the unique ability to detect cancer cells at their source before they form. This innovative technology can screen for early signs of cancer that other cancer screening methods fail to detect, providing earlier opportunities for treatment.